FDA Program discussion with leaders fr... - Lung Cancer Support

Lung Cancer Support

4,003 members2,170 posts

FDA Program discussion with leaders from patient advocacy groups.

Denzie profile image
DenzieModeratorVolunteer
0 Replies

When: Jun 8, 2023 2:30 PM- 4:00 PM Eastern Time (US and Canada)

Topic: FDA Patient Listening Session – Non-Small Cell Lung Cancer Patient Advocacy Groups

Join us for a discussion with patient advocacy groups, patients, and caregivers, who will share challenges and opportunities as they advocate for drug development in these molecular subgroups. 

Register in advance for this FDA Zoom webinar. Registration is open:

fda.zoomgov.com/webinar/reg...

Written by
Denzie profile image
Denzie
Moderator
To view profiles and participate in discussions please or .
Read more about...

You may also like...

First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)

available for patients without metastatic disease creates a new opportunity for early stage...

FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression

Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced...

Farewell to our dear friend Anita

travelled across the country as a patient advocate, speaking to groups of researchers. She was...

Has anyone received the Covid-19 Vaccine while taking Immunotherapy?

and other patients have been receiving this therapy longer than metastatic lung cancer patients...

A Milestone that Shouldn't Be!

baby-stepping through each day, one day at a time. The lung cancer remains stable, and my...